Abstract
Despite the moderate success of monoclonal antibodies and a number of pipeline drugs showing promise, the survival rate of gastric and oesophageal cancers is persistently poor. This needs to be addressed with further clinical development of more targeted therapies - and current market conditions are anticipated to boost rapid growth of such products.
Cite
CITATION STYLE
APA
Trewartha, D. (2014). On target. European Pharmaceutical Contractor, (Winter), 29–31. https://doi.org/10.12968/s0013-7758(22)90620-8
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free